NYSE:HAE - Haemonetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$90.92 +2.01 (+2.26 %)
(As of 05/22/2018 02:04 AM ET)
Previous Close$88.91
Today's Range$89.52 - $91.55
52-Week Range$38.47 - $91.55
Volume500,400 shs
Average Volume491,510 shs
Market Capitalization$4.75 billion
P/E Ratio48.62
Dividend YieldN/A
Beta0.9

About Haemonetics (NYSE:HAE)

Haemonetics logoHaemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer system, a blood diagnostic instrument that measure a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system, a surgical blood salvage system for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it offers SafeTrace Tx, a software solution that manages blood product inventory and transfusion, as well as performs patient cross-matching; and BloodTrack suite of solutions for managing, tracking, and controlling blood products from the hospital blood center through to transfusion to the patient. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:HAE
CUSIP40502410
Phone781-848-7100

Debt

Debt-to-Equity Ratio0.08
Current Ratio1.35
Quick Ratio0.94

Price-To-Earnings

Trailing P/E Ratio48.62
Forward P/E Ratio41.14
P/E Growth4.02

Sales & Book Value

Annual Sales$903.92 million
Price / Sales5.38
Cash Flow$3.6223 per share
Price / Cash25.10
Book Value$14.08 per share
Price / Book6.46

Profitability

EPS (Most Recent Fiscal Year)$1.87
Net Income$45.57 million
Net Margins5.04%
Return on Equity12.71%
Return on Assets7.89%

Miscellaneous

Employees3,107
Outstanding Shares53,450,000

Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How will Haemonetics' stock buyback program work?

Haemonetics declared that its board has approved a stock buyback program on Tuesday, February 6th 2018, which authorizes the company to repurchase $260,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its stock is undervalued.

How were Haemonetics' earnings last quarter?

Haemonetics (NYSE:HAE) issued its earnings results on Tuesday, May, 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.43. The medical instruments supplier had revenue of $233.55 million for the quarter, compared to the consensus estimate of $226.63 million. Haemonetics had a return on equity of 12.71% and a net margin of 5.04%. Haemonetics's revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.39 EPS. View Haemonetics' Earnings History.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Haemonetics.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY19 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $2.00-2.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.09.

What price target have analysts set for HAE?

6 analysts have issued 12-month price targets for Haemonetics' shares. Their forecasts range from $50.00 to $100.00. On average, they anticipate Haemonetics' share price to reach $81.40 in the next year. View Analyst Ratings for Haemonetics.

What are Wall Street analysts saying about Haemonetics stock?

Here are some recent quotes from research analysts about Haemonetics stock:
  • 1. Morgan Stanley analysts commented, "We are maintaining our Outperform rating for REGENXBIO. Today, after market close, the company reported 1Q18 results and provided an update on its pipeline. Key takeaways include: 1) all programs remain on track, with topline data from both the wet AMD and HoFH trials expected in late 2018; and 2) the two MPS programs are slated to dose the first patients in mid-2018. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $336 million pro forma, we continue to recommend REGENXBIO shares to risk-tolerant investors." (5/9/2018)
  • 2. According to Zacks Investment Research, "Over the past three months, Haemonetics has been outpeforming its industry. Haemonetics has been gaining on continued momentum in new business generation and geographical expansion. We are upbeat about Haemonetics’ consistent growth in the Plasma franchise. Strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth. The company is now focusing on the development and launch of NexSys PCS plasmapheresis system. The company’s strong cash position boosts investors’ confidence. The expansion in both gross and operating margin buoys optimism. The raised fiscal 2018 adjusted earnings guidance is also impressive.  However, we are disappointed with the fact that despite encouraging growth at the Plasma and Hospitals segment, the company’s sluggish Blood Center business moderated overall growth in the reporting cycle." (5/4/2018)

Are investors shorting Haemonetics?

Haemonetics saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 884,267 shares, a decrease of 32.0% from the March 30th total of 1,300,931 shares. Based on an average trading volume of 435,043 shares, the short-interest ratio is presently 2.0 days. Currently, 1.7% of the shares of the stock are sold short.

Who are some of Haemonetics' key competitors?

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:
  • Mr. Christopher Simon, Chief Exec. Officer, Pres and Director (Age 54)
  • Mr. William P. Burke, Chief Financial Officer and Exec. VP
  • Mr. Neil Ryding, Exec. VP of Global Operations (Age 57)
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 41)
  • Mr. Gerard J. Gould, VP of Investor Relations (Age 64)

Has Haemonetics been receiving favorable news coverage?

News coverage about HAE stock has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Haemonetics earned a daily sentiment score of 0.00 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 47.19 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.96%), Wells Fargo & Company MN (3.58%), Neuberger Berman Group LLC (3.25%), Dimensional Fund Advisors LP (2.90%), Victory Capital Management Inc. (2.82%) and Millennium Management LLC (2.21%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Institutional Ownership Trends for Haemonetics.

Which major investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Point72 Asset Management L.P., Neuberger Berman Group LLC, Wells Fargo & Company MN, Segall Bryant & Hamill LLC, WINTON GROUP Ltd, Royal Bank of Canada and Schwab Charles Investment Management Inc.. Company insiders that have sold Haemonetics company stock in the last year include Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Insider Buying and Selling for Haemonetics.

Which major investors are buying Haemonetics stock?

HAE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., BlackRock Inc., Columbus Circle Investors, OppenheimerFunds Inc., Federated Investors Inc. PA, Picton Mahoney Asset Management and Allianz Asset Management GmbH. View Insider Buying and Selling for Haemonetics.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $90.92.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $4.75 billion and generates $903.92 million in revenue each year. The medical instruments supplier earns $45.57 million in net income (profit) each year or $1.87 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (HAE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Haemonetics (NYSE:HAE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Haemonetics in the last 12 months. Their average twelve-month price target is $81.40, suggesting that the stock has a possible downside of 10.47%. The high price target for HAE is $100.00 and the low price target for HAE is $50.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.60
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $81.40$70.00$70.00$51.20
Price Target Upside: 10.47% downside2.13% upside2.13% upside5.60% downside

Haemonetics (NYSE:HAE) Consensus Price Target History

Price Target History for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Barrington ResearchBoost Price TargetOutperform$90.00LowView Rating Details
5/9/2018Jefferies GroupBoost Price TargetBuy$95.00LowView Rating Details
5/9/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$77.00 ➝ $100.00LowView Rating Details
2/7/2018JMP SecuritiesReiterated RatingOutperform$72.00HighView Rating Details
1/2/2018Raymond JamesUpgradeUnderperform ➝ Market PerformHighView Rating Details
11/8/2017Craig HallumReiterated RatingHold$40.00 ➝ $50.00N/AView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
11/7/2016BenchmarkBoost Price TargetHold$32.00 ➝ $34.00N/AView Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/AView Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform ➝ Market Perform$35.00N/AView Rating Details
8/15/2016SidotiDowngradeBuy ➝ Neutral$39.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Haemonetics (NYSE:HAE) Earnings History and Estimates Chart

Earnings by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Earnings Estimates

2018 EPS Consensus Estimate: $1.58
2019 EPS Consensus Estimate: $2.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.25$0.37$0.30
Q2 20183$0.38$0.47$0.44
Q3 20183$0.41$0.45$0.43
Q4 20182$0.40$0.43$0.42
Q1 20193$0.39$0.43$0.41
Q2 20193$0.52$0.57$0.55
Q3 20193$0.60$0.65$0.63
Q4 20193$0.56$0.64$0.60

Haemonetics (NYSE HAE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/8/2018Q4 2018$0.43$0.43$226.63 million$233.55 millionViewListenView Earnings Details
2/6/2018Q3 2018$0.44$0.62$227.79 million$234.04 millionViewListenView Earnings Details
11/7/2017Q2 2018$0.41$0.48$219.12 million$225.40 millionViewN/AView Earnings Details
8/7/2017Q1 2018$0.31$0.33$211.29 million$211.00 millionViewListenView Earnings Details
5/8/2017Q4 2017$0.37$0.39$215.06 million$228.10 millionViewListenView Earnings Details
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.51$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.51$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.45$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.35$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
11/1/2010Q2 2011$0.38$0.40ViewN/AView Earnings Details
8/2/2010Q1 2011$0.36$0.37ViewN/AView Earnings Details
5/4/2010Q4 2010$0.38$0.38ViewN/AView Earnings Details
2/1/2010Q3 2010$0.36$0.35ViewN/AView Earnings Details
11/2/2009Q2 2010$0.33$0.34ViewN/AView Earnings Details
8/3/2009Q1 2010$0.33$0.35ViewN/AView Earnings Details
5/4/2009Q4 2009$0.32$0.32ViewN/AView Earnings Details
2/2/2009Q3 2009$0.31$0.32ViewN/AView Earnings Details
10/27/2008Q2 2009$0.28$0.29ViewN/AView Earnings Details
8/1/2008Q1 2009$0.28$0.29ViewN/AView Earnings Details
5/1/2008Q4 2008$0.29$0.29ViewN/AView Earnings Details
1/31/2008Q3 2008$0.27$0.29ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Haemonetics (NYSE:HAE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Haemonetics (NYSE HAE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 97.34%
Insider Trading History for Haemonetics (NYSE:HAE)
Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/6/2018Dan GoldsteinVPSell518$54.65$28,308.704,002View SEC Filing  
3/6/2018Jacqueline ScanlanSVPSell114$72.23$8,234.22View SEC Filing  
3/6/2018Michelle L. BasilEVPSell389$72.23$28,097.47View SEC Filing  
1/2/2018Mark W KrollDirectorSell7,118$63.00$448,434.0033,881View SEC Filing  
12/1/2017Pedro P GranadilloDirectorSell7,118$57.06$406,153.0831,663View SEC Filing  
11/16/2017Ronald G GelbmanDirectorSell5,440$56.69$308,393.60View SEC Filing  
11/14/2017Willaim P BurkeCFOSell13,193$54.04$712,949.7227,227View SEC Filing  
11/13/2017Dan GoldsteinCAOSell4,691$54.93$257,676.633,747View SEC Filing  
11/10/2017Susan Bartlett FooteDirectorSell16,926$54.19$917,219.9427,313View SEC Filing  
5/22/2017Ronald MerrimanDirectorSell17,471$40.33$704,605.4324,925View SEC Filing  
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.9049,688View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.1822,088View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.7212,010View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.6845,350View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.1420,096View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.6120,464View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35147,040View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95147,040View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.9838,188View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.449,939View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.1814,901View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00130,307View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.0028,950View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.2614,901View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00130,307View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.0039,173View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00130,307View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.0016,905View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.8025,166View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00130,307View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.2216,905View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.0016,905View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00130,307View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.0016,905View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.6616,905View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00130,307View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.0010,987View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.0011,337View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.0011,337View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00115,798View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Haemonetics (NYSE HAE) News Headlines

Source:
DateHeadline
Haemonetics (HAE) Expected to Post Quarterly Sales of $219.52 MillionHaemonetics (HAE) Expected to Post Quarterly Sales of $219.52 Million
www.americanbankingnews.com - May 16 at 2:20 AM
Zacks: Analysts Expect Haemonetics (HAE) Will Post Earnings of $0.42 Per ShareZacks: Analysts Expect Haemonetics (HAE) Will Post Earnings of $0.42 Per Share
www.americanbankingnews.com - May 14 at 5:14 PM
Q1 2019 EPS Estimates for Haemonetics (HAE) Cut by Barrington ResearchQ1 2019 EPS Estimates for Haemonetics (HAE) Cut by Barrington Research
www.americanbankingnews.com - May 14 at 4:11 AM
Q3 2019 EPS Estimates for Haemonetics (HAE) Lifted by Barrington ResearchQ3 2019 EPS Estimates for Haemonetics (HAE) Lifted by Barrington Research
www.americanbankingnews.com - May 11 at 11:23 AM
Haemonetics (HAE) Lifted to B at TheStreetHaemonetics (HAE) Lifted to B at TheStreet
www.americanbankingnews.com - May 10 at 6:38 PM
Edited Transcript of HAE earnings conference call or presentation 8-May-18 12:00pm GMTEdited Transcript of HAE earnings conference call or presentation 8-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 4:35 PM
Is Eaton (ETN) a Great Stock for Value Investors?Is Eaton (ETN) a Great Stock for Value Investors?
finance.yahoo.com - May 10 at 4:35 PM
Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat EstimatesHaemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates
finance.yahoo.com - May 10 at 9:41 AM
Haemonetics (HAE) to Post Q1 2019 Earnings of $0.40 Per Share, Jefferies Group ForecastsHaemonetics (HAE) to Post Q1 2019 Earnings of $0.40 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 10 at 8:42 AM
Haemonetics (HAE) Given New $95.00 Price Target at Jefferies GroupHaemonetics (HAE) Given New $95.00 Price Target at Jefferies Group
www.americanbankingnews.com - May 9 at 5:12 PM
Barrington Research Increases Haemonetics (HAE) Price Target to $90.00Barrington Research Increases Haemonetics (HAE) Price Target to $90.00
www.americanbankingnews.com - May 9 at 3:17 PM
Haemonetics (HAE) Rating Reiterated by Morgan StanleyHaemonetics (HAE) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - May 9 at 3:12 PM
Haemonetics (HAE) PT Raised to $63 at Craig-HallumHaemonetics (HAE) PT Raised to $63 at Craig-Hallum
www.streetinsider.com - May 9 at 9:31 AM
Haemonetics 4th Quarter Fiscal 2018 Earnings Release Available on Investor ...Haemonetics 4th Quarter Fiscal 2018 Earnings Release Available on Investor ...
www.prnewswire.com - May 9 at 9:31 AM
Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief ...Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief ...
www.prnewswire.com - May 9 at 9:31 AM
Q1 2019 Earnings Estimate for Haemonetics (HAE) Issued By William BlairQ1 2019 Earnings Estimate for Haemonetics (HAE) Issued By William Blair
www.americanbankingnews.com - May 9 at 9:06 AM
Haemonetics (HAE) and Invuity (IVTY) Critical SurveyHaemonetics (HAE) and Invuity (IVTY) Critical Survey
www.americanbankingnews.com - May 8 at 11:18 PM
Haemonetics (HAE) Q4 2018 Results - Earnings Call TranscriptHaemonetics (HAE) Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 4:27 PM
Is It The Right Time To Buy Haemonetics Corporation (NYSE:HAE)?Is It The Right Time To Buy Haemonetics Corporation (NYSE:HAE)?
finance.yahoo.com - May 8 at 4:27 PM
Haemonetics (HAE) Posts  Earnings Results, Meets EstimatesHaemonetics (HAE) Posts Earnings Results, Meets Estimates
www.americanbankingnews.com - May 8 at 10:11 AM
Haemonetics (HAE) Releases FY19 Earnings GuidanceHaemonetics (HAE) Releases FY19 Earnings Guidance
www.americanbankingnews.com - May 8 at 9:52 AM
BRIEF-Haemonetics Reports Qtrly Earnings Per Share Of $0.22BRIEF-Haemonetics Reports Qtrly Earnings Per Share Of $0.22
www.reuters.com - May 8 at 9:23 AM
Haemonetics Q4 Profit Tops Estimates; Appoints Said Bolorforosh CTOHaemonetics Q4 Profit Tops Estimates; Appoints Said Bolorforosh CTO
www.nasdaq.com - May 8 at 9:23 AM
Haemonetics: Fiscal 4Q Earnings SnapshotHaemonetics: Fiscal 4Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:23 AM
Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology OfficerHaemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology Officer
finance.yahoo.com - May 8 at 9:23 AM
Haemonetics 4th Quarter Fiscal 2018 Earnings Release Available on Investor Relations WebsiteHaemonetics 4th Quarter Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - May 8 at 9:23 AM
Haemonetics (HAE) Receives Average Recommendation of "Buy" from BrokeragesHaemonetics (HAE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 7 at 1:08 AM
Haemonetics (HAE) Upgraded by Zacks Investment Research to HoldHaemonetics (HAE) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 5 at 1:07 AM
Haemonetics (HAE) Short Interest UpdateHaemonetics (HAE) Short Interest Update
www.americanbankingnews.com - May 3 at 1:40 AM
Haemonetics (HAE) Scheduled to Post Earnings on TuesdayHaemonetics (HAE) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 2:08 AM
Global Blood Collection Market 2018-2022 with Focus on Key Vendors - BD, Haemonetics, Quest Diagnostics & Thermo Fisher ScientificGlobal Blood Collection Market 2018-2022 with Focus on Key Vendors - BD, Haemonetics, Quest Diagnostics & Thermo Fisher Scientific
finance.yahoo.com - April 30 at 4:26 PM
Haemonetics (HAE) Expected to Post Quarterly Sales of $224.57 MillionHaemonetics (HAE) Expected to Post Quarterly Sales of $224.57 Million
www.americanbankingnews.com - April 29 at 4:43 AM
Haemonetics (HAE) Expected to Post Earnings of $0.43 Per ShareHaemonetics (HAE) Expected to Post Earnings of $0.43 Per Share
www.americanbankingnews.com - April 27 at 3:14 AM
Teleflex (TFX) versus Haemonetics (HAE) Critical ContrastTeleflex (TFX) versus Haemonetics (HAE) Critical Contrast
www.americanbankingnews.com - April 18 at 1:20 AM
BidaskClub Downgrades Haemonetics (HAE) to Strong SellBidaskClub Downgrades Haemonetics (HAE) to Strong Sell
www.americanbankingnews.com - April 15 at 1:17 PM
Haemonetics (HAE) Lifted to Sell at BidaskClubHaemonetics (HAE) Lifted to Sell at BidaskClub
www.americanbankingnews.com - April 12 at 6:15 PM
$224.57 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter$224.57 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter
www.americanbankingnews.com - April 12 at 4:37 AM
Haemonetics Co. (HAE) Receives Average Recommendation of "Hold" from AnalystsHaemonetics Co. (HAE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 12 at 1:29 AM
Haemonetics (HAE) Lifted to "Buy" at Zacks Investment ResearchHaemonetics (HAE) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:27 PM
Haemonetics Rides High on Plasma, Blood Center Remains WeakHaemonetics Rides High on Plasma, Blood Center Remains Weak
finance.yahoo.com - April 11 at 4:28 PM
Haemonetics (HAE) Lowered to "Sell" at Zacks Investment ResearchHaemonetics (HAE) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 10:25 AM
Insider Selling: Haemonetics Co. (HAE) VP Sells 518 Shares of StockInsider Selling: Haemonetics Co. (HAE) VP Sells 518 Shares of Stock
www.americanbankingnews.com - April 10 at 7:31 PM
Haemonetics Sets Date for Publishing Fourth Quarter Fiscal 2018 Results: May 8, 2018Haemonetics Sets Date for Publishing Fourth Quarter Fiscal 2018 Results: May 8, 2018
finance.yahoo.com - April 10 at 9:54 AM
Zacks: Analysts Anticipate Haemonetics Co. (HAE) Will Announce Earnings of $0.43 Per ShareZacks: Analysts Anticipate Haemonetics Co. (HAE) Will Announce Earnings of $0.43 Per Share
www.americanbankingnews.com - April 10 at 5:24 AM
Haemonetics (HAE) Upgraded to Strong-Buy by ValuEngineHaemonetics (HAE) Upgraded to Strong-Buy by ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM
Haemonetics' Plasma Tool Enhancement Gets 510(K) ClearanceHaemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
finance.yahoo.com - April 2 at 4:29 PM
Haemonetics Plasma Tool Enhancement Gets 510(K) ClearanceHaemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
feeds.benzinga.com - April 2 at 1:52 PM
Barrington Research Increases Haemonetics (HAE) Price Target to $57.00Barrington Research Increases Haemonetics (HAE) Price Target to $57.00
www.americanbankingnews.com - April 1 at 9:40 AM
Haemonetics (HAE) PT Raised to $51.00 at Morgan StanleyHaemonetics (HAE) PT Raised to $51.00 at Morgan Stanley
www.americanbankingnews.com - March 31 at 5:28 PM
Haemonetics (HAE) Raised to Overweight at Morgan StanleyHaemonetics (HAE) Raised to Overweight at Morgan Stanley
www.americanbankingnews.com - March 31 at 12:54 PM

SEC Filings

Haemonetics (NYSE:HAE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Haemonetics (NYSE:HAE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Haemonetics (NYSE HAE) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.